Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 1/20 | 0.60 |
| ▸ | ECE1 | P42892 | 1/20 | 0.60 |
| ▸ | CASP3 | P42574 | 2/20 | 0.59 |
| ▸ | CTSL | P07711 | 3/20 | 0.57 |
| ▸ | CTSS | P25774 | 3/20 | 0.57 |
| ▸ | CTSB | P07858 | 2/20 | 0.57 |
| ▸ | CTSK | P43235 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA5A | P35218 | 1/20 | 0.56 |
| ▸ | CTSD | P07339 | 1/20 | 0.56 |
| ▸ | CASP1 | P29466 | 1/20 | 0.56 |
| ▸ | CASP7 | P55210 | 1/20 | 0.56 |
| ▸ | CASP9 | P55211 | 1/20 | 0.56 |
| ▸ | CASP6 | P55212 | 1/20 | 0.56 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.56 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL951587 | 1.00 | MME (0.60) | MMEECE1CASP3CTSLCTSS | |
| SCHEMBL19776145 | 1.00 | MME (0.60) | MMEECE1CASP3CTSLCTSS | |
| SCHEMBL10452681 | 0.91 | MME (0.56) | MMEECE1CTSLCTSSCTSB | |
| SCHEMBL5689424 | 0.91 | CASP3 (0.58) | CASP3CTSLCTSSCTSBCTSK | |
| SCHEMBL13637586 | 0.91 | CASP3 (0.58) | CASP3CTSLCTSSCTSBCTSK | |
| SCHEMBL7378851 | 0.90 | ECE1 (0.64) | MMEECE1CASP3CTSLCTSS | |
| SCHEMBL6272667 | 0.90 | ECE1 (0.64) | MMEECE1CASP3CTSLCTSS | |
| SCHEMBL15947169 | 0.90 | CASP3 (0.57) | ECE1CASP3CTSLCTSSCTSB | |
| SCHEMBL7327620 | 0.89 | CAPN1 (0.64) | MMEECE1CASP3CTSLCTSS | |
| SCHEMBL19557810 | 0.89 | CASP3 (0.61) | CASP3CTSLCTSSCTSBCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4637748-A2 | PNU ANTHRACYCLINE-DERIVED LINKER-PAYLOADS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Merck Sharp & Dohme LLC (US) | 2025-10-29 | — | — | EP | disclosed |
| WO-2024137502-A2 | PNU ANTHRACYCLINE-DERIVED LINKER-PAYLOADS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-06-27 | — | — | WO | disclosed |
| EP-3814348-B9 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-3814348-B1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11713316-B2 | Substituted naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-01 | — | — | US | disclosed |
| US-20220324859-A1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-10-13 | — | — | US | disclosed |
| EP-3814348-A1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | Bristol-Myers Squibb Company (US) | 2021-05-05 | — | — | EP | disclosed |
| US-10954238-B1 | Substituted naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-03-23 | — | — | US | disclosed |
| US-10669272-B2 | Substituted naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-02 | — | — | US | disclosed |
| US-20200109140-A1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | SYNGENE INTERNATIONAL LIMITED (IN) | 2020-04-09 | — | — | US | disclosed |
| EP-0226304-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1991-08-28 | — | — | EP | disclosed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | disclosed |
| EP-0226304-A1 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1987-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324859-A1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKZ, DGKA, DGKG | MME 3121/4885ECE1 1607/4885CASP3 2197/4885 |
| US-20200109140-A1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKZ, DGKA, DGKG | MME 3121/4885ECE1 1607/4885CASP3 2197/4885 |
| US-11713316-B2 | Substituted naphthyridinone compounds useful as T cell activators | DGKZ, DGKA, DGKG | MME 3121/4885ECE1 1607/4885CASP3 2197/4885 |
| US-10669272-B2 | Substituted naphthyridinone compounds useful as T cell activators | DGKZ, DGKA, DGKG | MME 3121/4885ECE1 1607/4885CASP3 2197/4885 |
| US-10954238-B1 | Substituted naphthyridinone compounds useful as T cell activators | DGKZ, DGKA, DGKG | MME 3121/4885ECE1 1607/4885CASP3 2197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.